<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04146051</url>
  </required_header>
  <id_info>
    <org_study_id>MG-001</org_study_id>
    <nct_id>NCT04146051</nct_id>
  </id_info>
  <brief_title>Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)</brief_title>
  <official_title>Autologous T-Cells Expressing A Chimeric Antigen Receptor Directed To B-Cell Maturation Antigen (BCMA) In Patients With Generalized Myasthenia Gravis (MG)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cartesian Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cartesian Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase Ib/IIa study to evaluate the safety and preliminary efficacy of Descartes-08
      CAR T-cells in patients with Generalized Myasthenia Gravis
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 4, 2019</start_date>
  <completion_date type="Anticipated">April 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose</measure>
    <time_frame>28 days</time_frame>
    <description>Maximum Tolerated Dose (MTD)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Myasthenia Gravis -Activities of Daily Living Score</measure>
    <time_frame>Day 0 to Day 168</time_frame>
    <description>Change in Myasthenia Gravis of Daily Living Score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Myasthenia Gravis, Generalized</condition>
  <arm_group>
    <arm_group_label>Phase 1b Dose-Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Generalized Myasthenia Gravis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase IIa Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Generalized Myasthenia Gravis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Descartes-08</intervention_name>
    <description>Autogolous T-cells expressing a chimeric antigen receptor directed to BCMA</description>
    <arm_group_label>Phase 1b Dose-Escalation</arm_group_label>
    <arm_group_label>Phase IIa Expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient must be at least 18 years of age.

          -  Patient must have Generalized Myasthenia Gravis at the time of screening.

          -  Concomitant immunosuppressive drugs must be deemed necessary by the investigator.

        Exclusion Criteria:

          -  Major chronic illness that is not well managed at the time of study entry and in the
             opinion of the investigator may increase the risk to the patient.

          -  Patient is pregnant or lactating.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Study Trial Central Mailbox</last_name>
    <phone>302-648-6497</phone>
    <email>trials@cartesiantx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California Irvine</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Volkan Granit</last_name>
      <email>vgranit@med.miami.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>October 29, 2019</study_first_submitted>
  <study_first_submitted_qc>October 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 31, 2019</study_first_posted>
  <last_update_submitted>June 11, 2020</last_update_submitted>
  <last_update_submitted_qc>June 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Descartes-08</keyword>
  <keyword>CART</keyword>
  <keyword>CAR-T</keyword>
  <keyword>Autoimmune</keyword>
  <keyword>Auto-antibody</keyword>
  <keyword>Auto antibody</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscle Weakness</mesh_term>
    <mesh_term>Myasthenia Gravis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

